Dihydropyridine calcium channel blocker
Pregnancy: Can be used in second/third trimester for hypertension. Avoid in first trimester.
Nifedipine (Modified-release)
Brand names: Adalat LA, Adipine MR, Coracten XL
Adult dose
Dose: 30–60 mg modified-release once daily; range 20–90 mg/day
Route: Oral (MR formulation — swallow whole)
Frequency: Once daily (LA) or twice daily (SR)
Max: 90 mg/day
Hypertension: 30 mg OD (LA), increase to 60–90 mg. Angina: 30–60 mg OD. Raynaud's phenomenon: 10–20 mg TDS (immediate-release) or 30 mg OD (MR). Avoid short-acting formulations for HTN/angina (reflex tachycardia, excess MI risk).
Paediatric dose
Dose: 0.25 mg/kg
Route: Oral
Frequency: Three times daily
Max: 3 mg/kg/day
Hypertensive emergency (acute): 0.25–0.5 mg/kg immediate-release (unlicensed route; swallow, do not crush for sublingual use). Specialist guidance required. Modified-release not suitable for children (swallowing difficulty).
Dose adjustments
Renal
No dose adjustment required.
Hepatic
Reduce dose in severe hepatic impairment.
Paediatric weight-based calculator
Hypertensive emergency (acute): 0.25–0.5 mg/kg immediate-release (unlicensed route; swallow, do not crush for sublingual use). Specialist guidance required. Modified-release not suitable for children (swallowing difficulty).
Clinical pearls
- Modified-release ONLY for hypertension and angina — never use short-acting for these indications
- Peripheral oedema responds to dose reduction or switch to amlodipine
- Grapefruit juice increases nifedipine bioavailability — avoid
- First-line for Raynaud's phenomenon (reduces peripheral vasospasm)
- Amlodipine preferred for hypertension in most guidelines (longer half-life, smoother)
Contraindications
- Cardiogenic shock
- Significant aortic stenosis
- Acute MI within 4 weeks
- Short-acting formulation for angina or hypertension (excess MI risk)
Side effects
- Peripheral oedema (common — capillary leak)
- Flushing
- Headache
- Reflex tachycardia (especially short-acting)
- Hypotension
- Gingival hyperplasia (prolonged use)
- Constipation
Interactions
- CYP3A4 inhibitors (grapefruit juice, erythromycin) — increase nifedipine levels
- CYP3A4 inducers (rifampicin) — reduce nifedipine levels
- Beta-blockers — additive negative inotropic effect
- Antihypertensives — additive hypotension
Monitoring
- Blood pressure
- Heart rate
- Oedema
- LFTs (prolonged use)
Reference: BNFc; BNF; NICE CG127 Hypertension; ESC Hypertension Guidelines 2023. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Modified Mallampati Classification · Airway Assessment
- Modified Early Warning Score (MEWS) · Early Warning
- Modified Shock Index (MSI) · Haemodynamic Assessment
- Modified Sgarbossa's Criteria (Smith Modification) for MI in LBBB · ECG Interpretation
- MAGGIC Heart Failure Risk Score · Heart Failure
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
Pathways